Manfred Mosk, Ph.D.

Manfred Mosk

Manfred Mosk is President of Technomedics Management & Systems, Inc., a life sciences consultancy focused primarily on the biopharmaceutical and biotechnology sectors and the field of pharmaco-economics. He recently co-founded and is a director of NanoGB13, Inc., a company that is in the pre-clinical development stage with a number of novel nano pro-drugs that, when linked to selected chemotherapeutics, could potentially treat a variety of cancers characterized by low life expectancy.

Previously, Dr. Mosk co-founded and was a director of ImmunoCellular Therapeutics, Ltd., which is clinically testing vaccines that can induce a patient’s immune system to attack and destroy tumors in the brain (glioblastoma multiforme), and is also developing a number of additional product candidates to treat multiple cancer indications. Prior to that, Dr. Mosk was chairman of Duska Therapeutics, Inc., which clinically developed new formulations of ATP (adenosine 5’-triphosphate) for the treatment of bradycardic syncope (a sudden brief loss of consciousness and posture). This company—which had concluded a cooperative agreement with Medtronic, Inc.—was subsequently acquired by a group of private investors.

In previous years, Dr. Mosk was the co-founder, the president/CEO, and a director of Medco Research, Inc., which raised capital through an initial public stock offering, obtained exclusive rights to certain formulations of adenosine from the University of Virginia School of Medicine, completed a clinical research program, and obtained FDA approval to market both Adenocard for the treatment of paroxysmal supraventricular tachycardia and, later, Adenoscan as a pharmacological stressor that—in conjunction with cardiac imaging—detects coronary artery disease in subjects who cannot test maximally on a treadmill. Medco Research was acquired by King Pharmaceuticals, which in turn was bought by Pfizer, Inc. Dr. Mosk also served for several years as an economic counselor to Pfizer for the development of its business and the conduct of its operations in several countries of Eastern Europe.

As co-founder and executive vice president of Rom-Amer Pharmaceuticals, Inc., Dr. Mosk obtained exclusive rights for U.S. and Canadian territories from the then-government of Romania to a drug that was marketed in Eastern and Western Europe. Under FDA guidance, Rom-Amer conducted a clinical trial at Duke University for the treatment of depression geared to the geriatric population, and the company was acquired by a group of private investors upon completion of that compound’s initial phase of human testing.

Before Dr. Mosk’s career as an entrepreneur/executive in the biotechnology field, he spent a total of ten years in executive positions with Eastman Dillon Union Securities & Co. and J. Barth & Co., investment banking firms that are members of the New York Stock Exchange. He was responsible for certain aspects of investment management portfolios for clients and later was associated with mergers and acquisitions of small healthcare companies.

Dr. Mosk holds B.S., M.S., and Ph.D. degrees in business administration from California State University and California Western University, and also completed the executive program in pharmaceutical sciences from the Institute for Applied Pharmaceutical Sciences in the U.S. Dr. Mosk has served on the board of directors of UCLA’s Jonsson Cancer Center Foundation and The California State University Foundation, and is currently a member of the board of governors and serves on a committee of the board of directors of Cedars-Sinai Medical Center, having also previously served on the Institutional Review Board of that institution. Dr. Mosk joined University Kidney Research Organization (UKRO) as a director in the organization’s early days, and has also financially supported its activities.

Dr. Mosk has been a member of the American Association of Pharmaceutical Scientists, the International Society of Pharmacoeconomics and Outcomes Research, the American Society of Health Economists, the National Association of Business Economists, the Society of Stem Cell Research, the American Heart Association, and the New York Academy of Sciences. He is fluent in Romanian and German.

 

Share Button

Comments are closed